Cytokeratin 8 Level in Age-related Macular Degeneration

• Status: Completed
• Trial end date: 2018-04-23
• Target enrollment: 0
• Participant gender: All

Summary

The investigators will evaluate the concentrations of cytokeratin 8 in aqueous humor in eyes with exudative age-related macular degeneration (AMD) before therapy with intravitreal Ranibizumab, and identify associations with visual and anatomical outcome after treatment.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gangnam Severance Hospital
• Collaborators: Inje University; Konkuk University; Novartis; Severance Hospital
• Treatments: Ranibizumab

Criteria

Inclusion Criteria:

1. Treatment-naive neovascular AMD patients requiring intravitreal injection of Ranibizumab

2. A recent onset of disease confirmed by history and clinical findings.

3. Patient is required to be least 50 years of age

Exclusion Criteria:

1. Myopia with a refractive error >-3.0 diopters or evidence of pathologic myopia (pre-operative refractive data were used to assess pseudophakic eyes)

2. Any history of vitrectomy, anti-VEGF therapy, or photodynamic therapy (PDT)

3. History of cataract surgery within 3 months prior to presentation

4. Evidence of end-stage AMD such as subfoveal fibrosis or atrophy

5. Evidence of other retinal diseases including central serous chorioretinopathy and other neovascularmaculopathies; glaucoma; poor imaging data caused by media opacity; or unstable fixation

6. Patients with uncontrolled systemic diseases, use of immunosuppressive drugs, or malignant tumors of any location